Jan B. W.
- Country
- Germany
- Department
- Hämostaseologie - Gerinnung
Research Overview
- Safety, Dose-Finding, and Pharmacodynamic Study of BAY 3389934 in Patients with Sepsis-Associated Coagulopathy
- Phase 3 Trial of VMX-C001 Versus Usual Care in Patients on Factor Xa DOACs Requiring Urgent High-Bleeding-Risk Surgery or Invasive Procedures
- A Randomized Study of Andexanet Alfa Compared to Usual Care in Patients Receiving a Factor Xa Inhibitor who Require Urgent Surgery or Procedure (ANNEXA-RS)
Data & Insights
Has run more than one trial at 133 of 397 partner sites.
Specializations
Anticoagulation Management
This investigator specializes in the reversal of anticoagulation effects, particularly focusing on patients taking Factor Xa inhibitors who require urgent surgical interventions. Their research encompasses managing bleeding risks in emergency surgical scenarios.
- Factor Xa inhibitor reversal agents
- Emergency surgical procedures
- Bleeding risk management
Cancer-Associated Thrombosis
The investigator studies venous thromboembolism (VTE) in cancer patients, with particular attention to gastrointestinal and genitourinary cancers. Their work evaluates novel therapeutic approaches for preventing VTE recurrence in oncology patients.
- Cancer-related VTE management
- Gastrointestinal cancer complications
- Genitourinary cancer treatments
Critical Care Medicine
The investigator conducts research in critical care conditions, specifically focusing on sepsis and associated coagulopathy. Their work involves investigating novel therapeutic approaches for managing complex bleeding disorders in critically ill patients.
- Sepsis treatment
- Coagulation disorders
- Critical care interventions
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.